Cargando…

Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion

Patients with lower-grade gliomas (LGGs) have highly diverse clinical outcomes. Although histological features and molecular markers have been used to predict prognosis, the identification of new biomarkers for the accurate prediction of patient outcomes is still needed. The serine synthesis pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shang-Pen, Chan, Yung-Chieh, Huang, Shang-Yu, Lin, Yuan-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016949/ https://www.ncbi.nlm.nih.gov/pubmed/31861486 http://dx.doi.org/10.3390/cancers12010013

Ejemplares similares

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas
por: Huang, Shang-Pen, et al.
Publicado: (2021)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
por: Pesenti, Chiara, et al.
Publicado: (2017)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
por: Lv, Lei, et al.
Publicado: (2021)

Enrichment of Aldolase C Correlates with Low Non-Mutated IDH1 Expression and Predicts a Favorable Prognosis in Glioblastomas
por: Chang, Yu-Chan, et al.
Publicado: (2019)

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status
por: Bader, Jakob Maximilian, et al.
Publicado: (2022)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
por: Kim, Gi Jeong, et al.
Publicado: (2023)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

A “Weighted” Fluorescence In Situ Hybridization Strengthens the Favorable Prognostic Value of 1p/19q Codeletion in Pure and Mixed Oligodendroglial Tumors
por: Senetta, Rebecca, et al.
Publicado: (2013)

The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations
por: Siakallis, Loizos, et al.
Publicado: (2023)

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion
por: Li, Guanzhang, et al.
Publicado: (2021)

A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
por: Zhu, Zheng, et al.
Publicado: (2020)

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
por: Arita, Hideyuki, et al.
Publicado: (2020)

How I treat anaplastic glioma without 1p/19q codeletion
por: Berghoff, Anna, et al.
Publicado: (2019)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
por: Hata, Nobuhiro, et al.
Publicado: (2016)

The T2-FLAIR Mismatch Sign as an Imaging Indicator of IDH-Mutant, 1p/19q Non-Codeleted Lower Grade Gliomas: A Systematic Review and Diagnostic Accuracy Meta-Analysis
por: Adamou, Antonis, et al.
Publicado: (2021)

RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion
por: Chen, Sean Chun-Chang, et al.
Publicado: (2019)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
por: Pandith, Arshad A, et al.
Publicado: (2020)

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas
por: Ball, Matthew K, et al.
Publicado: (2020)

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas
por: Gilhodes, Julia, et al.
Publicado: (2023)

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
por: Chakrabarty, Satrajit, et al.
Publicado: (2023)

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
por: Filipski, Katharina, et al.
Publicado: (2019)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
por: Habiba, Umma, et al.
Publicado: (2021)

FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling
por: Kang, Ho, et al.
Publicado: (2021)

Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
por: Li, Yan-Xi, et al.
Publicado: (2016)

Predicting chromosome 1p/19q codeletion by RNA expression profile: a comparison of current prediction models
por: Wang, Zhi-liang, et al.
Publicado: (2019)

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma
por: Lin, Wanzun, et al.
Publicado: (2021)

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
por: Lee, Julieann, et al.
Publicado: (2018)

Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status
por: Wang, Ning, et al.
Publicado: (2019)

Prediction of 1p/19q Codeletion in Diffuse Glioma Patients Using Pre-operative Multiparametric Magnetic Resonance Imaging
por: Kim, Donnie, et al.
Publicado: (2019)

Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pbs2l0kilipha57302el2t5huq